ADMA submitted PAS in DEC 2018, where they had manufacturing facility issues that have since been resolved. Ri-002 (Ascentiv) was approved April 1,2019 where our previous ADMA position ran over 50%. We are looking for ADMA to get its second approval, since both BIVIGAM and RI-002 are made at the same facility.
On previous runup- ADMA ran over 30% pre-catalyst. This previous friday 5/3/2019 ADMA broke up and out the bull flag (triangle) formation and continuously ran, closing the day up over 9%. Looking at the historical chart pattern since receiving its CRL Dec. 2018; Adma has had a repeating pattern, after making higher lows since December, SP would retrace approximately .786, where we kept adding to our positions. ADMA has now formed another Vector Wave( exclusive to Biotech algorithmic trading). I am looking for a continued run back around $5.50 up to the potential PDUFA catalyst for Bivigam. LT SP projection is $7.50-8.00.
On previous runup- ADMA ran over 30% pre-catalyst. This previous friday 5/3/2019 ADMA broke up and out the bull flag (triangle) formation and continuously ran, closing the day up over 9%. Looking at the historical chart pattern since receiving its CRL Dec. 2018; Adma has had a repeating pattern, after making higher lows since December, SP would retrace approximately .786, where we kept adding to our positions. ADMA has now formed another Vector Wave( exclusive to Biotech algorithmic trading). I am looking for a continued run back around $5.50 up to the potential PDUFA catalyst for Bivigam. LT SP projection is $7.50-8.00.